CO5700794A2 - Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas - Google Patents
Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidasInfo
- Publication number
- CO5700794A2 CO5700794A2 CO06073023A CO06073023A CO5700794A2 CO 5700794 A2 CO5700794 A2 CO 5700794A2 CO 06073023 A CO06073023 A CO 06073023A CO 06073023 A CO06073023 A CO 06073023A CO 5700794 A2 CO5700794 A2 CO 5700794A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- cyclodextrin
- antimicrobial
- preservants
- cyclodextrines
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
1.- Una composición farmacéutica con una mejor tolerancia en el sitio de inyección que comprende una cantidad terapéuticamente efectiva de un ingrediente farmaceuticamente activo, una ciclodextrina ß, un conservante farmacéuticamente aceptable, un vehículo farmacéuticamente aceptable, y un excipiente opcional farmacéuticamente aceptable, en donde el conservante demuestra eficacia como conservante antimicrobiano farmacéuticamente aceptable y en donde el ingrediente farmacéuticamente activo es un compuesto de fórmula I, Io sus sales farmacéuticarnente aceptables en donde R2 se selecciona entre el grupo constituido por metilo, etilo, isopropilo, sec-butilo y terc-butilo.2.- Una composición farmacéutica de acuerdo con la reivindicación 1, en donde ciclodextrina ß es 2-hidroxipropil - ciclodextrina ß ó sulfobutil eter - ciclodextrina ß.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700794A2 true CO5700794A2 (es) | 2006-11-30 |
Family
ID=34910697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06073023A CO5700794A2 (es) | 2004-01-30 | 2006-07-26 | Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (es) |
| EP (1) | EP1713504B1 (es) |
| JP (1) | JP5021318B2 (es) |
| KR (1) | KR100834232B1 (es) |
| CN (1) | CN101090735A (es) |
| AR (2) | AR047469A1 (es) |
| AU (1) | AU2005216709B2 (es) |
| BR (1) | BRPI0506496B8 (es) |
| CA (1) | CA2554346C (es) |
| CO (1) | CO5700794A2 (es) |
| CY (1) | CY1119188T1 (es) |
| DK (1) | DK1713504T3 (es) |
| ES (1) | ES2638113T3 (es) |
| HU (1) | HUE034099T2 (es) |
| IL (1) | IL176676A0 (es) |
| LT (1) | LT1713504T (es) |
| NO (1) | NO20063858L (es) |
| NZ (1) | NZ548236A (es) |
| PL (1) | PL1713504T3 (es) |
| PT (1) | PT1713504T (es) |
| RU (1) | RU2332997C2 (es) |
| SI (1) | SI1713504T1 (es) |
| TW (1) | TW200524632A (es) |
| WO (1) | WO2005082416A2 (es) |
| ZA (1) | ZA200605148B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200567T1 (hr) * | 2011-11-29 | 2020-06-26 | Jurox Pty Ltd | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| CN105377235A (zh) * | 2013-07-19 | 2016-03-02 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
| KR102308973B1 (ko) | 2013-12-04 | 2021-10-08 | 베링거잉겔하임베트메디카게엠베하 | 개선된 피모벤단의 약제학적 조성물 |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
| WO2020167476A1 (en) * | 2019-02-15 | 2020-08-20 | Saol International Limited | Injectable phenol formulations and methods of their use |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| AT527172A1 (de) | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| SK278788B6 (sk) | 1991-05-31 | 1998-02-04 | Pfizer Inc. | Chinuklidínové deriváty, spôsob ich prípravy a pou |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| DK0668863T3 (da) | 1992-11-12 | 1997-06-30 | Pfizer | Quinuclidinderivat som substans P-antagonist |
| US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| CA2342797A1 (en) * | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| AU5975700A (en) | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CA2448722A1 (en) * | 2001-07-20 | 2003-02-06 | Pfizer Products Inc. | Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses |
| WO2003072141A1 (en) | 2002-02-22 | 2003-09-04 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| EP1713506A1 (en) | 2004-01-30 | 2006-10-25 | Pfizer Products Incorporated | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration |
| BRPI0507325A (pt) | 2004-01-30 | 2007-07-03 | Pfizer Prod Inc | antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia |
| AU2005210259A1 (en) | 2004-02-02 | 2005-08-18 | Pfizer Products Inc. | Process for preparation of 1-(2S,3S)-2-benzhydr yl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine |
-
2005
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en not_active IP Right Cessation
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en not_active Ceased
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es not_active Expired - Lifetime
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en not_active Expired - Lifetime
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en not_active Expired
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko not_active Expired - Lifetime
- 2005-01-17 CA CA002554346A patent/CA2554346C/en not_active Expired - Lifetime
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja not_active Expired - Lifetime
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230382A1 (es) | Nueva composicion farmaceutica para administracion de farmacos | |
| AR109357A2 (es) | Composición farmacéutica parenteral con tolerancia en el sitio de inyección | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| CO6220955A2 (es) | Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CO6241104A2 (es) | "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp" | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| CO6321158A2 (es) | Formulacion oral | |
| PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| CO6351721A2 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| AR074309A1 (es) | Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo | |
| AR029412A1 (es) | Forma cristalina | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| DOP2021000073A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| CL2004001843A1 (es) | Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax | |
| AR056369A1 (es) | Compuestos derivados de quinazolina y composicion farmaceutica | |
| CR10210A (es) | Derivados de benzoisoindol para el tratamiento del dolor | |
| AR033596A1 (es) | Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno | |
| AR050947A1 (es) | Derivados de 3,4-dihidro-3-metil-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxilato | |
| AR026451A1 (es) | Compuestos heterociclicos sililados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |